Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
14 déc. 2021 07h00 HE
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
01 déc. 2021 16h05 HE
|
Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
01 oct. 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
05 août 2021 07h30 HE
|
Wave Life Sciences USA, Inc.
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in...
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
02 juin 2021 16h52 HE
|
Wave Life Sciences USA, Inc.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating...
Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications
12 mai 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
13 avr. 2021 07h45 HE
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
22 févr. 2021 08h30 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
11 janv. 2021 08h00 HE
|
Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...
Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies
15 oct. 2020 08h00 HE
|
Translate Bio, Inc.
-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly...